<b>Background/Objective:</b> Breast cancer (BC) management has traditionally relied on static clinicopathologic and immunohistochemical biomarkers (hormone receptor status, HER2 expression, and proliferative activity assessed at diagnosis). The gene discussed is ERBB2; the disease is breast cancer.